Literature DB >> 34187536

Deciding the operation type according to mismatch repair status among hereditary nonpolyposis colorectal cancer patients: should a tailored approach be applied, or does one size fit all?

Chun-Kai Liao1, Yueh-Chen Lin1, Yu-Jen Hsu1, Yih-Jong Chern1, Jeng-Fu You1, Jy-Ming Chiang2,3.   

Abstract

BACKGROUND: Although extended colectomy (EC) was recommended for HNPCC patients, previous studies did not show significantly improved overall survival. Immunohistochemical (IHC) stain of mismatch repair (MMR) gene protein expression is now a feasible and reliable test clinically. Therefore, we tried to investigate whether we could use MMR IHC stain to select operation types in HNPCC patients. PATIENTS AND METHODS: Between 1995 and 2013, 186 HNPCC patients were collected. Status of MMR protein expression, perioperative clinic-pathological variables and post-operative follow up status were analyzed by multivariate analyses.
RESULTS: Sixty-five percent (121 of 186) patients of these HNPCC patients demonstrated loss of at least one MMR protein. There were several significant differences existing between deficient MMR (dMMR) and proficient MMR (pMMR) subgroups in terms of clinic-pathological characteristics. With the average follow-up duration of 93.9 months, we observed significantly high risk of developing metachronous CRC between SC and EC subgroups (crude rate 8.5% vs. 0%, p = 0.035). However, no significant difference was observed among the presence of extra-colonic tumors (12.4% vs. 5.8%, p = 0.284). The positive and negative prediction rate of metachronous CRC in dMMR subgroup was 12.8 and 87.2% while 1.9 and 98.1% in the pMMR subgroup. Survival outcomes were significantly affected by MMR status and resection types by multivariate analysis. Significantly better OS in dMMR subgroup (HR = 0.479, 95% CI: 0.257-0.894, p = 0.021) comparing with pMMR subgroup was observed. However, significant improved DFS (HR = 0.367, 95% CI: 0.172-.0787, p = 0.010) but not significant for OS (HR = 0.510, 95% CI: 0.219-1.150, p = 0.103) for EC subgroup compared with SC subgroup. Differences existing among different subgroups by combing extent of resection and MMR status. In dMMR subgroup, SC, compared with EC, demonstrated significantly worse DFS by multivariate analyses (HR = 3.526, 95% CI: 1.346-9.236, p = 0.010) but not for OS (HR = 2.387, 95% CI: 0.788-7.229, p = 0.124), however, no significantly differences of OS and DFS in pMMR subgroup between SC and EC were found.
CONCLUSIONS: Significantly better overall survival and higher rate of metachronous CRC exist in dMMR subgroup of HNPCC patients comparing with pMMR subgroup. Extended colectomy significantly improved DFS and was thus recommended for dMMR subgroup but not pMMR subgroup of HNPCC patients.

Entities:  

Keywords:  Extended colectomy; HNPCC; MMR status; Metachronous CRC; Overall survival

Year:  2021        PMID: 34187536     DOI: 10.1186/s13053-021-00186-x

Source DB:  PubMed          Journal:  Hered Cancer Clin Pract        ISSN: 1731-2302            Impact factor:   2.857


  8 in total

1.  Quality of life after surgery for colon cancer in patients with Lynch syndrome: partial versus subtotal colectomy.

Authors:  Jasmijn F Haanstra; Wouter H de Vos Tot Nederveen Cappel; Jessica P Gopie; Juda Vecht; Steven A L W Vanhoutvin; Annemieke Cats; Hester J van der Zaag-Loonen; Alexandra M J Langers; Jerry H W Bergmann; Paul C van de Meeberg; Evelien Dekker; Jan H Kleibeuker; Hans F A Vasen; Fokko M Nagengast; Peter van Duijvendijk
Journal:  Dis Colon Rectum       Date:  2012-06       Impact factor: 4.585

2.  Clinicopathologic and pedigree differences in amsterdam I-positive hereditary nonpolyposis colorectal cancer families according to tumor microsatellite instability status.

Authors:  Laura Valle; Jose Perea; Pablo Carbonell; Victoria Fernandez; Ana M Dotor; Javier Benitez; Miguel Urioste
Journal:  J Clin Oncol       Date:  2007-01-16       Impact factor: 44.544

Review 3.  ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.

Authors:  Sapna Syngal; Randall E Brand; James M Church; Francis M Giardiello; Heather L Hampel; Randall W Burt
Journal:  Am J Gastroenterol       Date:  2015-02-03       Impact factor: 10.864

4.  Cost-effectiveness of alternative colonoscopy surveillance strategies to mitigate metachronous colorectal cancer incidence.

Authors:  Fatih Safa Erenay; Oguzhan Alagoz; Ritesh Banerjee; Adnan Said; Robert R Cima
Journal:  Cancer       Date:  2016-06-01       Impact factor: 6.860

5.  Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families.

Authors:  Wouter H de Vos tot Nederveen Cappel; Fokko M Nagengast; Gerrit Griffioen; Fred H Menko; Babs G Taal; Jan H Kleibeuker; Hans F Vasen
Journal:  Dis Colon Rectum       Date:  2002-12       Impact factor: 4.585

6.  Differential features of colorectal cancers fulfilling Amsterdam criteria without involvement of the mutator pathway.

Authors:  Xavier Llor; Elisenda Pons; Rosa M Xicola; Antoni Castells; Cristina Alenda; Virgínia Piñol; Montserrat Andreu; Sergi Castellví-Bel; Artemio Payá; Rodrigo Jover; Xavier Bessa; Anna Girós; Anna Roca; Miquel A Gassull
Journal:  Clin Cancer Res       Date:  2005-10-15       Impact factor: 12.531

7.  Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers.

Authors:  Aung Ko Win; Susan Parry; Bryan Parry; Matthew F Kalady; Finlay A Macrae; Dennis J Ahnen; Graeme P Young; Lara Lipton; Ingrid Winship; Alex Boussioutas; Joanne P Young; Daniel D Buchanan; Julie Arnold; Loïc Le Marchand; Polly A Newcomb; Robert W Haile; Noralane M Lindor; Steven Gallinger; John L Hopper; Mark A Jenkins
Journal:  Ann Surg Oncol       Date:  2013-01-29       Impact factor: 5.344

Review 8.  Surgical treatment of hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome).

Authors:  Miguel A Rodriguez-Bigas; Gabriela Möeslein
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.